In het nieuws

November 2017

Het Reumafonds presenteert: Gentherapie bij reuma: De stand van zaken.

September 2017

Janneke Meulenberg (COO) en Ingrid de Vries (Research Technician) zullen aanwezig zijn op het Cell Therapy Manufacturing & Gene Therapy Congress 6 – 7 December 2017 in de RAI, Amsterdam.

 

Op woensdag 20 september zal Janneke Meulenberg, COO, spreken op het congres Phacilitate, Cell and Gene Therapy Europe 2017, in Berlijn. Ook de CEO van Arthrogen, Robert Jan Lamers, is aanwezig

 

Arthrogen's COO, Janneke Meulenberg, presenteert op woensdag 13 september de case study: Production Platforms for RA Gene Therapy Applications op de 'Cell and Gene Therapy Manufacturing' conferentie in Londen


Juli 2017

Oproep van het Reumafonds: http://www.reumafonds.nl/informatie-voor-doelgroepen/patienten/help-mee/neem-deel-aan-onderzoek.


Juni 2017

Arthrogen zal deelnemen aan de EULAR Annual European Congress of Rheumatology, Madrid 14-17 juni 2017


Mei 2017

Arthrogen’s CEO Robert Jan Lamers presenteert op 22 – 23 mei, 2017 bij de BioEquity in Paris

Arthrogen zal deelnemen aan de jaarbijeenkomst van de American Society of Gene & Cell Therapy, ASGCT, Washington, 10-13 mei 2017

Arthrogen’s CEO Robert Jan Lamers presenteert op 3 mei, 2017 bij de Investment Summit for Advanced Therapies, in Londen


 Maart 2017

Artikel in het Leidsch Dagblad: winst-voor-reumapatienten


Februari 2017

Arthrogen in het nieuws: http://labiotech.eu/arthrogen-gene-therapy-rheumatoid-arthritis/


16 Februari, 2017

Today, biopharmaceutical company Arthrogen announced the approval for the ART-I02 gene therapy clinical phase Ib study in patients with rheumatoid arthritis. The clinical trial will focus on rheumatoid arthritis patients who, despite multiple treatments with existing medicines, still suffer from inflamed joints. The new approach is unique in that it aims to stimulate the local production of an anti-inflammatory protein within the inflamed joint by means of a single treatment. A virus is used to deliver a piece of genetic material into the joint, which will then produce its own anti-inflammatory protein in the inflamed area, only when needed. It is expected that one single injection will have a long-lasting effect. This initial trial will be used to examine safety and the first signs of effects. The study will be executed by the Centre for Human Drug Research (CHDR) in Leiden in close collaboration with University Medical Centers in the Netherlands.. Lees meer


Februari 2017

Publicatie:
Empty Capsids and Macrophage Inhibition/Depletion Increase rAAV Transgene Expression in Joints of Both Healthy and Arthritic Mice. The researchers present evidence demonstrating the synergistic enhancement of transgene expression achieved when the two pre-treatments were combined. Lees meer


Januari 2017

Arthrogen’s COO Janneke Meulenberg PhD. en CEO Robert Jan Lamers zullen aanwezig zijn op de Cell & Gene Therapy World 2017 in Miami, van 17 tot 20 januari 2017. Op donderdag 19 januari om 10.50-11.30am presenteert Janneke Meulenberg “AAV-mediated gene therapy for rheumatoid arthritis: toward clinical trials with ART-I02” op de Biotech Showcase sessie. Voor meeting verzoeken kunt u gebruik maken van het Phacilitate meeting system, het contact formulier op www.arthrogen.nl of de Arthrogen LinkedIn pagina.


Januari 2017

Arthrogen CEO Robert Jan Lamers will be present at the janauary 9-12, 2017 JP Morgan Healthcare Conference. For meeting requests please use the contact formulier on our site or LinkedIn.